Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5610163 | 0.84 | CYP1A2 (0.52) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL5609497 | 0.82 | IGF1R (0.53) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL11288839 | 0.82 | CYP1A2 (0.68) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL143961 | 0.82 | CYP1A2 (0.68) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL6546754 | 0.77 | IGF1R (0.64) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL6546878 | 0.77 | CYP1A2 (0.62) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL42362 | 0.77 | — | — | |
| SCHEMBL19263826 | 0.74 | CYP1A2 (0.59) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL10452106 | 0.74 | CYP1A2 (0.59) | CYP1A2CYP2A6TAAR1IDO1HRH3 | |
| SCHEMBL5493944 | 0.74 | CYP1A2 (0.59) | CYP1A2CYP2A6TAAR1IDO1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | claimed |
| EP-4313943-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200208-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | WO | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | claimed |
| US-5500428-A | Furyl-substituted purines and adenosine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-03-19 | — | — | US | claimed |
| US-5300509-A | Adenosine antagonists for treating cardiovascular disorders, vasodilation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-05 | — | — | US | claimed |
| EP-0544445-A2 | Furyl-substituted purines, oxazolopyrimidines and pteridines as adenosine antagonists | ZENECA LIMITED (GB) | 1993-06-02 | — | — | EP | claimed |
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | disclosed |
| EP-4313943-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022268520-A1 | USE OF SUBSTITUTED PYRROLIDINONES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE OF PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022200208-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | WO | disclosed |
| US-7538215-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| US-5500428-A | Furyl-substituted purines and adenosine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-03-19 | — | — | US | disclosed |
| US-5300509-A | Adenosine antagonists for treating cardiovascular disorders, vasodilation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-05 | — | — | US | disclosed |
| EP-0544445-A2 | Furyl-substituted purines, oxazolopyrimidines and pteridines as adenosine antagonists | ZENECA LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199542-A1 | SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | HPD, DDT, PPOX | CYP1A2 44/4885CYP2A6 350/4885TAAR1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.